Insmed, Inc. (INSM)
97.76
+3.59
(+3.81%)
USD |
NASDAQ |
Jun 09, 14:26
Insmed SG&A Expense (Quarterly) : 247.26M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Madrigal Pharmaceuticals, Inc. | 268.52M |
| United Therapeutics Corp. | 156.60M |
| PTC Therapeutics, Inc. | 86.18M |
| Protagonist Therapeutics, Inc. | 13.28M |
| Alnylam Pharmaceuticals, Inc. | 322.55M |